Adial Pharmaceuticals Inc (ADIL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.86 (-6.72%), Market cap $0.01B, 52-week low–high $0.14 ~ $3.12.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Financial statements, price targets, institutional (13F) holdings and related news for Adial Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Adial Pharmaceuticals Inc trades at $4.86 (-6.72%). Real-time quotes and charts are available on BlackAll Trade.
Adial Pharmaceuticals Inc has a market cap of about $0.01B.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's le